Pharmaceutical compositions and methods of treating dry eye disorders
AssigneePfizer Inc.
InventorsChanning R. Beals, Elizabeth WoldeMussie, Hovhannes John Gukasyan, Jingwen Ma
Life of this patent
Estimating the term…
Abstract
Inhibitors of Janus kinase-3 (“Jak3”) are useful for treating dry eye disorders and other disorders requiring the wetting of the eye. Jak3 inhibitors useful for treating eye disorders include the compound 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile.
Claims10
A method for the treatment of an inflammation-linked ocular disorder selected from the group consisting of glaucoma, uveitis, diabetic retinopathy, age-related macular degeneration and dry eye, comprising administering topically to the eye of a mammal in need thereof a topical ophthalmic composition comprising a pharmaceutically effective amount of a Janus kinase-3 (“Jak3”) inhibitor having the structure
- or a pharmaceutically effective salt thereof.
A method for restoration of normal tear production in a mammal comprising, administering topically to the eye of a mammal in need thereof a topical ophthalmic composition comprising a pharmaceutically effective amount of a Janus kinase-3 (“Jak3”) inhibitor having the structure 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile.
Dependencies are inferred from the claim text.